NYSE · BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
$43.00▼ 0.72% ($0.31)at close
After hours$42.84▼ 0.37%7:49 PM ET
Valuation
Cash-flow DCF
Verdict: fairly priced. Price between Bear and Base.
The price holds with free cash flow shrinking 2.8% a year for 5 years. Our scenarios assume −5.2–24.8%.
That's below its past 10-year pace of 9.8%.
Value per share
Base case
$82.68
Price used $43.00 is 48% below this
USD · TTM ending Jun 30, 2026 · Price Oct 14, 8:00 PM UTC
The trailing effective tax rate was 5.0%, outside the 5.0% to 40.0% range a rate held for ten years and beyond should sit in, so the 21.0% default is used for NOPAT and the WACC tax shield.
3 more notes
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Reported total debt includes capitalised leases (~1% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.
Free cash flow each value needs
Free cash flow today $3.3B. The price needs $3.8B by 2036. Base case: $6.9B. At its recent pace: $8.5B. Bear to Bull: $3B to $19.1B.
Free cash flow today $3.3B. The price needs $3.8B by 2036. Base case: $6.9B. At its recent pace: $8.5B. Bear to Bull: $3B to $19.1B.
Free cash flow in 2036
today $3.3B
−$3.2Bless than the Base case
Value per share · Base case
$82.68
Price $43.00
48% below this
- Stage 1 growth, yrs 1–5
- 9.8%
- Stage 2 growth, yrs 6–10
- 5.4%
- Discount rate
- 6.8%
The trailing effective tax rate was 5.0%, outside the 5.0% to 40.0% range a rate held for ten years and beyond should sit in, so the 21.0% default is used for NOPAT and the WACC tax shield.
3 more notes
FCFF base normalized by replacing latest capex with the company's trailing median capex-to-revenue ratio.
Historical FCFF CAGR and the default growth rates are taken from the raw historical series. The valuation base is normalized for the current-period DCF.
Reported total debt includes capitalised leases (~1% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.
USD · TTM ending Jun 30, 2026 · Price Oct 14, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 55.32% over the last year. Revenue grew 13.53% over the trailing twelve months. Operating margin moved from 16.1% to 21.46%. Free cash flow grew 9.48% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 3rd percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
What would invalidate this read
This read changes if operating margin (currently 21.46%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe.
Market multiples
Stock splits
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
37
Buy
7
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Oct 28, 2026
Q3 FY26 · EPS est $0.75 · Revenue est $5.1B
Same quarter, year over year
FY26 YTD +10.7%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $1.66 vs $1.50 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $3.05
- +21.5%
- FY24
- $2.51
- —
Q2 FY26
Reported Jul 29, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.86
Estimate
$0.84
Year over year
+14.7%
Vs prior quarter
+7.5%
Institutional Sentiment
Boston Scientific Corporation · BSX
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.